ADMA Biologics (ADMA) Reports Q4 Loss of $0.58
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/9/2026
- Wall St rises as chip stocks' gains offset Middle East jitters
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil eases as investors assess US-Iran peace prospects
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- GameStop stockholders approve share count increase to 2.5 billion
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- AI bubble fears mount as Zuckerberg admits agent delays and Burry shorts sector
- S&P 500 ends down after Trump says Iran deal is 'over'
ADMA Biologics Reports Year End 2015 Financial Results, Accomplishments and Upcoming Milestones
March 23, 2016 4:27 PM EDTRAMSEY, N.J., March 23, 2016 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced its financial results for the year ended December 31, 2015, and outlined the companys 2015 accomplishments and anticipated milestones for 2016.
During 2015 we achieved several meaningful milestones, including the filing and acceptance of a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for our lead product candidate, RI-002, received patent protection for... More
